Penumbra, Inc.

NYSE:PEN

Medical - Devices

Healthcare
$320.60 -0.72%

-$2.30 today

Market cap
$12.64B
Beta
0.70
P/E (TTM)
72.6
EPS (TTM)
$4.36
52W Low $221.26High $362.41

Volume 0.21M

Average 0.50M

PEN Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Penumbra, Inc.NYSE: PEN

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow grows, but more slowly than its trailing trend

Q2 FY2026 free cash flow of $32.54M rose 10.8% year over year, behind the +33.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 55.6% from the prior quarter.

Context

  • Free cash flow amounted to 12.5% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Free cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.8% toward the trailing-twelve-month pace of +33.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$32.54M-55.6% QoQ
Last fiscal yearDec 2025
$174.93M+18.8% YoY
LTMJun 2026
$215.91M+33.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year+18.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
174.93M USD
Year-over-year change
+18.8%

Free Cash Flow vs competitors

How PEN compares with its peers on the latest reported figures

  • PEN's LTM Jun 2026 free cash flow of $215.91M is the 7th largest of the 9 companies compared; the peer median is $2.52B.
  • Its year-over-year change of +33.6% is the 5th highest of 9, against a peer median of +43.6%.
  • Free cash flow amounts to 14.3% of revenue for PEN, versus a peer median of 18.0%.
PEN Competitors Peer median
Free Cash Flow for PEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Jun 2026$8.72B +28.7%-1.8%18.7%
MDTMedtronic plcLTM Jul 2026$6.13B +15.6%+5.8%16.3%
BSXBoston Scientific CorporationLTM Jun 2026$3.63B +9.5%+58.8%17.3%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$3.6B +58.4%+37.5%31.1%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.43B +135.8%+11.9%22.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$252.22M +5.1%+45.3%15.7%
PENPenumbra, Inc.LTM Jun 2026$215.91M +33.6%—14.3%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$79.12M +92.4%+49.8%30.9%
ANGOAngioDynamics, Inc.LTM Feb 2026$1.5M +105.3%+8.3%0.5%
Peer median (excluding PEN) $2.52B+43.6%+24.7%18.0%

Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.28M(2M)90.95M14.01M177.69M
Depreciation & Amortization16.41M24.32M27.26M23.7M17.47M
Deferred Income Tax(14.09M)1.46M(19.06M)(16.34M)21.03M
Stock-Based Compensation00046.16M59.21M
Change in Working Capital(66.71M)(121.54M)(79.08M)(23.78M)(42.72M)
Accounts Receivables(21.34M)(69.86M)(266K)26.6M(19.51M)
Inventory(51.55M)(74.63M)(67.71M)(65.66M)(26.48M)
Accounts Payables(1.57M)13.39M1.1M4.17M3.07M
Other Working Capital7.75M9.57M(12.21M)11.11M213K
Other Non-Cash Items68.61M42.1M77.27M124.72M5.97M
Operating Cash Flow9.5M(55.66M)97.33M168.48M238.66M
Capital Expenditures(21.18M)(19.3M)(15.21M)(21.18M)(63.73M)
Acquisitions (Net)2.92M0(988K)00
Purchases of Investments(126.79M)0(81.94M)(32.91M)(355.74M)
Sales of Investments123.72M74.09M82.57M130.62M14.88M
Other Investing Activities(400K)0(500K)1.1M0
Investing Cash Flow(21.74M)54.79M(16.08M)77.62M(404.59M)
Debt Repayment(1.45M)(1.75M)(1.98M)(2.28M)(2.49M)
Common Stock Issued18.37M21.55M20.41M17.17M31.82M
Common Stock Repurchased000(100.39M)0
Dividends Paid00000
Other Financing Activities(16.08M)(8.18M)(2.23M)(1.52M)(2.8M)
Financing Cash Flow836K11.62M16.2M(87.01M)26.53M
Effect of Forex Changes1.11M(272K)168K(2.18M)1.89M
Net Change in Cash(10.29M)10.48M97.63M156.92M(137.51M)
Free Cash Flow(11.68M)(74.96M)82.12M147.3M174.93M

Penumbra, Inc.

NYSE:PEN

Intrinsic Alpha fair value

Locked

Current Price

$320.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.